Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Mirum Pharmaceuticals. The associated price target remains the same with $81.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Swayampakula Ramakanth has given his Buy rating due to a combination of factors surrounding Mirum Pharmaceuticals’ strategic acquisition of Bluejay Therapeutics. This acquisition significantly enhances Mirum’s portfolio in the rare liver disease sector by adding brelovitug, a promising monoclonal antibody targeting hepatitis B and delta viruses, which are associated with severe liver conditions.
Mirum’s management anticipates brelovitug to achieve peak sales of at least $750 million, with a substantial portion coming from the U.S. market. The acquisition is expected to provide immediate synergies and several near-term growth catalysts, positioning Mirum as a potential leader in the rare liver disease space. The ongoing Phase 3 studies of brelovitug, with interim results expected in 2026, further bolster the company’s growth prospects, making the stock an attractive buy for investors.
In another report released yesterday, Evercore ISI also maintained a Buy rating on the stock with a $94.00 price target.
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MIRM in relation to earlier this year.